Adipositas hat weltweit eine zunehmende Inzidenz und ist mit vielen Komorbiditäten assoziiert. Auch verschiedene Karzinomerkrankungen treten bei Adipositas vermehrt auf. Adipositas ist z.B. ein unabhängiger Risikofaktor für die Entstehung des postmenopausalen Hormonrezeptor-positiven Mammakarzinoms. Der genaue Pathomechanismus ist weiterhin Gegenstand der Forschung. Fest steht aber, dass bei einer Brustkrebserkrankung ein erhöhter BMI mit einem schlechteren Überleben assoziiert ist. In diesem Beitrag wird die Evidenz der Korrelation von Adipositas zum Mammakarzinom vorgestellt.
3
The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects).
Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: A pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2014; 383: 970-983
4
Di Angelantonio E,
Bhupathiraju SN,
Wormser D.
et al. Body-mass index and all-cause mortality: Individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388: 776-786
5
Dobbins M,
Decorby K,
Choi BCK.
The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med 2013; 2013
7
World Health Organization.
Research on the menopause in the 1990s: Report of a WHO Scientific Group. Geneva; 1996. Im Internet (Stand: 02.03.2021). https://apps.who.int/iris/handle/10665/41841
9
Suzuki R,
Orsini N,
Saji S.
et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status – a metaanalysis. Int J Cancer 2009; 124: 698-712
11
Bhaskaran K,
Douglas I,
Forbes H.
et al. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5·24 million UK adults. Lancet 2014; 384: 755-765
12
Renehan AG,
Tyson M,
Egger M.
et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
13
Chan DSM,
Vieira AR,
Aune D.
et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014; 1901- 1914;
14
Neuhouser ML,
Aragaki AK,
Prentice RL.
et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol 2015; 1: 611-621
20
Winder AA,
Kularatna M,
MacCormick AD.
Does Bariatric Surgery Affect the Incidence of Breast Cancer Development? A Systematic Review. Obes Surg 2017; 27: 3014-3020
21
Tao W,
Santoni G,
Euler-Chelpin MV.
et al. Cancer Risk After Bariatric Surgery in a Cohort Study from the Five Nordic Countries. Obes Surg 2020; 3761–3767
22
Sjöström L,
Gummesson A,
David Sjöström C.
et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncology 2009; 10: 653-662
23
Åsa A,
Taube M,
Peltonen M.
et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol 2017; 145: 224-229
24
Bhardwaj P,
Au CC,
Benito-Martin A.
et al. Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol 2019; 189: 161-170
26
Enriori CL,
Orsini W,
Del Carmen Cremona M.
et al. Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: Reversible effect of weight loss. Gynecol Oncol 1986; 23: 77-86
30
Stumvoll M,
Nurjhan N,
Perriello G.
et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554
31
Decensi A,
Puntoni M,
Goodwin P.
et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461
32
Martinez JA,
Chalasani P,
Thomson CA.
et al. Phase II study of metformin for reduction of obesity-associated breast cancer risk: A randomized controlled trial protocol. BMC Cancer 2016; 16: 500
33
Metformin CD.
A potentially winning therapeutic strategy to prevent breast cancer progression in overweight postmenopausal patients. Transl Cancer Res 2018; 7: 1306-1309
37
Holzer RG,
Park E-J,
Li N.
et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 2011; 147: 173-184
38
Freedman LS,
Clifford C,
Messina M.
Analysisof Dietary Fat, Calories, Body Weight, and the Development of Mammary Tumors in Rats and Mice: A Review. Cancer Res 1990; 50: 5710-5719
